472.80
+4.03%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Bafna Pharmaceuticals
Its shares trade on NSE under the ticker BAFNAPH.NS. It has been listed since 27 June 2008. In the fiscal year to 31 March 2026, it reported revenue of ₹1.51bn and net income of ₹111.0m. At that date it held total assets of ₹1.76bn and shareholders' equity of ₹961.5m.
Bafna Pharmaceuticals Ltd. engages in the manufacture of drugs and medicines of life saving drugs. The company is headquartered in Chennai, Tamil Nadu. The company went IPO on 2008-06-27. The firm is primarily engaged in the business of manufacturing finished pharmaceutical formulations. The company is also involved in manufacturing 336 licensed pharmaceutical formulations and has globally registered approximately 78 of its products. Its Madhavram facility manufactures finished solid oral and liquid oral dosage forms of Betalactam and Non-Betalactam and Cephalosporin products. The company supplies its products to the United Kingdom, Europe, and Australian markets. The firm's Grantlyon facility has the capability to supply both small-scale clinical trial quantities and commercial-scale requirements.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 27 Jun 2008
- Employees
- 588
- Website
- bafnapharma.com ↗
Leadership
Pay as last reported
- Ms. Shanmugam HemalathaExecutive Chairman of the Board, Whole Time Director, since 2020₹1.4m
- Mr. Bafna ChandChief Executive Officer, since 2020₹1.3m
- Mr. Melagiri SridharChief Financial Officer
- Mr. A. MohanachandranChief Compliance Officer, Company Secretary
- Mrs. Akilapriya RajuNon-Executive Non Independent Director
- Mr. Upendar ReddyNon-Executive Non-Independent Director
- Mrs. Ravichandran ChitraNon-Executive Independent Director₹66,000
- Mr. Navin KumarAdditional Non-Executive Independent Director
- Mr. Palamadai SundaresanNon-Executive Independent Director₹154,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Manufactures life-saving drugs and medicines
- Employs 588 full-time employees
- Produces 336 licensed pharmaceutical formulations
Weaknesses
- No specific weaknesses mentioned in the provided information
- No details on financial performance or market share provided
- No information on product diversification beyond the mentioned formulations
Opportunities
- Global registration of approximately 78 products
- Supply to United Kingdom, Europe, and Australian markets
- Capability to supply both clinical trial and commercial-scale requirements
Threats
- No specific threats mentioned in the provided information
- No details on competition or regulatory challenges provided
- No information on potential market saturation or economic factors
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.